Lineage Cell Therapeutics Inc. — Director's Dealing 2016

Apr 12, 2016

FORM 4
-----------	--

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
MOHANTY ADITYA P.	BIOTIME INC [ BTX ]
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	__ X __ Director _____ 10% Owner
		__ X __ Officer (give title below) _____ Other (specify below)
		Co-Chief Executive Officer
1010 ATLANTIC AVENUE, SUITE 102	4/7/2016
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	7. Nature of Indirect Beneficial
			Code	V	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Shares, no par value	4/11/2016		A		67567 (1)	A	\$2.96	67567	D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Option to Purchase Common Shares	\$3.16	4/7/2016		A		375000		(2)	4/6/2026	Common Shares	375000	\$0.00	375000	D
Restricted Stock Units	(3)	4/11/2016		A		75000		(4)	(4)	Common Shares	75000	\$0.00	75000	D
Option to Purchase Common Shares	\$3.78							(5)	12/28/2024	Common Shares	675000		675000	D

Explanation of Responses:

( 1) Grant of fully vested restricted stock under the BioTime 2012 Equity Incentive Plan.

( 2) One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

( 3) Grant of restricted stock units under the BioTime 2012 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share.

( One quarter of the restricted stock units shall vest upon the completion of 12 months of continuous employment from the date of grant and the balance shall vest in twelve equal quarterly installments thereafter upon completion of each quarter of continuous employment.

4)

( 5) 1/48th of the number of options will vest at the end of each full month of employment after December 29, 2014.

Reporting Owners

Reporting Owner Name / Address		Relationships
	Director	10% OwnerOfficer		Other
MOHANTY ADITYA P. 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA, CA 94501	X		Co-Chief Executive Officer

/s/Aditya P. Mohanty 4/11/2016 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.